Orion Oyj

Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
15 JANUARY 2026 at 16:30 EET

Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting

The Nomination Committee of Orion Corporation has on 15 January 2026 given to the company’s Board of Directors its recommendation on the proposal to the Annual General Meeting of 2026 concerning the composition of the Board of Directors to be elected by the meeting. The Committee recommends that the following proposal be presented to the Annual General Meeting of 2026:

Recommendation on the number of members of the Board of Directors and its composition

The number of Board members would be eight.

Of the present members of the Board, Kari Jussi Aho, Ari Lehtoranta, Veli-Matti Mattila, Hilpi Rautelin, Henrik Stenqvist and Karen Lykke Sørensen would be re-elected for the next term of office, and Minna Maasilta and Sophie Papa would be elected as new members.

Veli-Matti Mattila would be re-elected as Chairman of the Board.

Of the present members, Eija Ronkainen and Maziar Mike Doustdar are no longer available for re-election.

Minna Maasilta, born in 1986, holds a Master of Science (Eng.) and an MBA degree. Maasilta has had a long career in water and environmental engineering. She is currently the Managing Director of Maa- ja vesitekniikan tuki ry.

Sophie Papa, born in 1976, holds a Bachelor of Arts degree, a Bachelor of Medicine, Bachelor of Surgery degree and a PhD degree. Papa has had a long career in the fields of medicine and biotechnology. She is currently Consulting Venture Partner at RA Capital, Chief Medical Officer at several biotechnology companies and Clinical Reader (Associate Professor) in Immune Oncology at King’s College London.

Brief presentations of Minna Maasilta and Sophie Papa are attached to this recommendation. Presentations of the current Board Members are available on the company’s website at www.orionpharma.com/investors/corporate-governance/board-of-directors/.

Recommendation on remuneration to be paid to members of the Board of Directors

In addition, the Nomination Committee announces as its recommendation that the following remunerations be paid to the Board of Directors:

As an annual fee, the Chairman would receive EUR 120,000, the Vice Chairman would receive EUR 73,000 and the other members would receive EUR 60,000 each. However, if a member of the Board acts as the Chairman of the Audit Committee or the R&D Committee, her/his annual fee would be EUR 73,000.

In addition, as a fee for each meeting attended, the Chairman would receive EUR 1,200, the Vice Chairman would receive EUR 900, and the other members would receive EUR 600 each. The travel expenses of the Board members would be paid in accordance with the previously adopted practice. The aforementioned meeting attendance fees would also be paid to the Chairmen and to the members of the committees established by the Board. The meeting attendance fees of Board members permanently resident outside Finland would be doubled if the meeting was held outside the country of residence of such a member and the person attended the meeting at the place of the meeting.

Of the above-mentioned annual fees, 60 percent would be paid in cash and 40 percent in Orion Corporation B shares, which would be acquired for the members over the period 24–30 April 2026 from the stock exchange in amounts corresponding to EUR 48,000 for the Chairman, EUR 29,200 for the Vice Chairman and for the Board members acting as the Chairmen of the Audit Committee and the R&D Committee, and EUR 24,000 for each of the other members. The part of the annual fee that is to be paid in cash corresponds to the approximate sum necessary for the payment of the income taxes on the fees and would be paid no later than 29 May 2026. The annual fees shall encompass the full term of office of the Board of Directors.

In addition, the company would pay the transfer tax related to the part of the annual fee of the Board of Directors paid in shares.

Potential statutory social security and pension costs incurring to Board members having permanent residence outside Finland would be borne by Orion Corporation as required by the applicable national legislation.

Board members would be required to retain ownership of the Orion Corporation B shares paid as fees for a period of two years from the date of payment of the fees. However, if the person's membership of the Board of Directors of the company were to end before the expiry of the restriction on transfer, the restriction on transfer would expire at the end of the membership of the Board of Directors.

The Nomination Committee has not given its recommendation on the remuneration of the Board of Directors to the Board of Directors, but the matter will be proposed by a shareholder at the Annual General Meeting.

The members of the Nomination Committee belonging to the Board of Directors did not participate in the consideration or decision-making regarding the recommendation on the remuneration of the Board of Directors.

The Nomination Committee has consisted of the following members: Hilpi Rautelin, Chair, Annika Ekman, Petteri Karttunen, Risto Karvonen, Veli-Matti Mattila and Seppo Salonen.

Orion Corporation

                                                                         
Contact person:
Hilpi Rautelin, Chair of the Nomination Committee

Tel. +358 40 550 1920

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.

Attachment

• Presentations of the new Board members recommended by the Orion Nomination Committee